ArticleThe Journal of antimicrobial chemotherapy2026
Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
objectiveThe incidence of bloodstream infection (BSIs) due to extended-spectrum β-lactamase (ESBL) producing Escherichia coli is increasing worldwide. There is controversy as to whether ESBL production in itself is associated with higher mortality. The aim of this study is to evaluate the impact of ESBL production on mortality in BSIs due to E. coli considering the effect of confounders.
methodsPROBAC study is a prospective, multicentre, cohort study performed in 26 Spanish hospitals (October 2016-March 2017). All patients with E. coli BSIs were included. The outcome variable was all-cause 30-day mortality. Confounding was controlled by calculating a propensity score (PS) for ESBL production using baseline variables. PS were used as covariable, for matching, for inverse probability of treatment weight analysis and for stratified analysis within the PS quartiles.
resultsA total of 2394 cases were included, of which 322 (13.5%) were ESBL-producing isolates. The frequency of appropriate empirical treatment, in ESBL-producing and non-ESBL-producing isolates, was 53.7% and 92.0%, respectively. Thirty-day mortality was 14.6% in ESBL-producing isolates versus 9.6% in non-ESBL-producing isolates (P = 0.006), for a crude OR of 1.61 (95% CI: 1.14-2.27; P = 0.006). When we adjusted by PS and appropriate empirical treatment, the OR changed to 1.12 (95% CI: 0.75-1.67; P = 0.584). Other PS applications provided similar results.
conclusionBSIs due to ESBL-producing E. coli were associated with higher mortality in the crude analyses; however, the estimate of the association is reduced after adjustment for baseline variables and empirical therapy, and is not significant in matched analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.